Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 28, 2025, titled "Press Release".
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharma reported Q1 FY26 (quarter ended June 30, 2025) consolidated revenue of Rs. 3,178 crores, up 11% year-on-year, with operating EBITDA at Rs. 1,032 crores (up 14%) at a 32.5% margin. Net profit after tax rose 20% YoY to Rs. 548 crores from Rs. 457 crores. Standalone net profit was Rs. 551 crores (EPS Rs. 16.28). India business grew 11% to Rs. 1,811 crores, US revenues jumped 19% to Rs. 308 crores, Brazil rose 11% to Rs. 218 crores, and Germany grew 9% to Rs. 308 crores (latter impacted by a third-party supply disruption). R&D spend rose 16% to Rs. 157 crores. The Board also approved issuance of unsecured/secured redeemable non-convertible debentures or bonds via private placement within existing borrowing limits.
Strong Q1 with double-digit revenue and 20% profit growth signals healthy operational momentum and should be viewed positively by shareholders. However, the separate ongoing Rs. 11,917 crore acquisition of J.B. Chemicals & Pharmaceuticals, combined with the fresh NCD issuance plan, points to materially higher leverage ahead, which may weigh on near-term sentiment despite current strong earnings.